

Xiaotong Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1886826/publications.pdf>

Version: 2024-02-01

50
papers

564
citations

759233

12
h-index

752698

20
g-index

54
all docs

54
docs citations

54
times ranked

709
citing authors

#	ARTICLE	IF	CITATIONS
1	Second primary tumor after immune checkpoint inhibitor therapy: A case report. Thoracic Cancer, 2022, , .	1.9	5
2	Predictive Value of Echocardiographic Strain for Myocardial Fibrosis and Adverse Outcomes in Autoimmune Diseases. Frontiers in Cardiovascular Medicine, 2022, 9, 836942.	2.4	4
3	Response to letter to the editor by Zhang et al.. European Journal of Neurology, 2022, , .	3.3	0
4	Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis. Thoracic Cancer, 2022, 13, 1059-1066.	1.9	2
5	Clinical characteristics and prognostic model for extensive-stage small cell lung cancer: A retrospective study over an 8-year period. Thoracic Cancer, 2022, 13, 539-548.	1.9	5
6	Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study. Journal of Neurology, 2022, 269, 4808-4816.	3.6	11
7	Differential Regulation of the Immune System in Peripheral Blood Following Ischemic Stroke. BioMed Research International, 2022, 2022, 1-15.	1.9	2
8	Efficacy and safety of camrelizumab combined with chemotherapy (irinotecan combined with) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 small cell lung cancer: A phase II study.. Journal of Clinical Oncology, 2022, 40, 8573-8573.	1.6	0
9	Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study. Cancer Medicine, 2021, 10, 188-198.	2.8	11
10	Genomic characteristics of driver genes in Chinese patients with non-small cell lung cancer. Thoracic Cancer, 2021, 12, 357-363.	1.9	15
11	Blood eosinophil count-guided corticosteroid therapy and as a prognostic biomarker of exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110287.	2.5	13
12	Correlation between total homocysteine and cerebral small vessel disease: A Mendelian randomization study. European Journal of Neurology, 2021, 28, 1931-1938.	3.3	31
13	Myocarditis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy.. Journal of Clinical Oncology, 2021, 39, e14579-e14579.	1.6	0
14	High Level of Uromodulin Increases the Risk of Hypertension: A Mendelian Randomization Study. Frontiers in Cardiovascular Medicine, 2021, 8, 736001.	2.4	11
15	Effects of laser debonding treatment on the optical and mechanical properties of all-ceramic restorations. Lasers in Medical Science, 2021, 36, 1497-1504.	2.1	5
16	Lacune and Large Perivascular Space: Two Kinds of Cavities Are of Different Risk Factors and Stroke Risk. Cerebrovascular Diseases, 2020, 49, 522-530.	1.7	10
17	<p>NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score</p>. Cancer Management and Research, 2020, Volume 12, 5975-5985.	1.9	7
18	Influenza in hospitalised patients with malignancy: a propensity score matching analysis. ESMO Open, 2020, 5, e000968.	4.5	4

#	ARTICLE	IF	CITATIONS
19	A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test. <i>Tumor Biology</i> , 2020, 42, 101042832095860.	1.8	3
20	A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096584.	3.2	7
21	Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study. <i>Thoracic Cancer</i> , 2020, 11, 1869-1875.	1.9	1
22	Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non-small cell lung cancer and ERBB2 mutation. <i>Thoracic Cancer</i> , 2020, 11, 2051-2055.	1.9	10
23	Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum-pemetrexed: The first report of two cases. <i>Thoracic Cancer</i> , 2020, 11, 2339-2342.	1.9	3
24	Single-center study to determine the safety and efficacy of CT-707 in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 1216-1223.	1.9	5
25	Marked elevation of creatine phosphokinase alone caused by sintilimab - beware of hypothyroid myopathy. <i>European Journal of Cancer</i> , 2020, 128, 57-59.	2.8	7
26	Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 2406-2430.	1.9	40
27	Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib. <i>Thoracic Cancer</i> , 2020, 11, 594-602.	1.9	14
28	Histologic transformation of lung cancer during pembrolizumab therapy: A case report. <i>Thoracic Cancer</i> , 2020, 11, 793-796.	1.9	10
29	Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events. <i>Thoracic Cancer</i> , 2020, 11, 1746-1751.	1.9	11
30	Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 1647-1654.	1.9	18
31	Opportunistic bowel infection after corticosteroid dosage tapering in a stage IV lung cancer patient with tislelizumab-related colitis. <i>Thoracic Cancer</i> , 2020, 11, 1699-1702.	1.9	8
32	Prediction of OCT images of short-term response to anti-VEGF treatment for neovascular age-related macular degeneration using generative adversarial network. <i>British Journal of Ophthalmology</i> , 2020, 104, 1735-1740.	3.9	28
33	Non-motor Symptoms in Chinese Patients With Isolated Generalized Dystonia: A Case-Control Study. <i>Frontiers in Neurology</i> , 2020, 11, 209.	2.4	5
34	Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients. <i>Thoracic Cancer</i> , 2020, 11, 1621-1632.	1.9	44
35	Opportunistic infections complicating immunotherapy for non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 1689-1694.	1.9	11
36	Association between lipoprotein(a) concentration and the risk of stroke in the Chinese Han population: a retrospective case-control study. <i>Annals of Translational Medicine</i> , 2020, 8, 212-212.	1.7	14

#	ARTICLE	IF	CITATIONS
37	Influenza in hospitalized cancer patients: A propensity score matching analysis.. Journal of Clinical Oncology, 2020, 38, 170-170.	1.6	0
38	A validated ultra-HPLC-MS/MS method for determination of honokiol in human plasma and its application to a clinical pharmacokinetic study. Bioanalysis, 2019, 11, 1085-1098.	1.5	5
39	Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease. OncoTargets and Therapy, 2019, Volume 12, 5545-5549.	2.0	4
40	Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. Thoracic Cancer, 2019, 10, 551-556.	1.9	42
41	Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy. OncoTargets and Therapy, 2018, Volume 11, 7513-7519.	2.0	6
42	Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy. Lung Cancer, 2018, 125, 142-149.	2.0	34
43	Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. Lung Cancer, 2018, 122, 32-37.	2.0	32
44	Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation. Lung Cancer, 2018, 122, 1-6.	2.0	17
45	Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma. Thoracic Cancer, 2018, 9, 1056-1061.	1.9	7
46	Rebiopsy status among non-small cell lung cancer patients after Icotinib therapy in China.. Journal of Clinical Oncology, 2018, 36, e21146-e21146.	1.6	0
47	ERBB2 mutation profiling with next-generation sequencing (NGS) in solid tumors.. Journal of Clinical Oncology, 2018, 36, e24264-e24264.	1.6	0
48	The ability of avitinib to penetrate the blood brain barrier and its control of intra-/extra- cranial disease in patients of non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation.. Journal of Clinical Oncology, 2017, 35, e20613-e20613.	1.6	7
49	Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China. Clinica Chimica Acta, 2015, 438, 388-395.	1.1	30
50	The role of epidermal growth factor receptor mutations (EGFRm) in NSCLC with leptomeningeal metastasis: A prospective observational study.. Journal of Clinical Oncology, 2015, 33, e19070-e19070.	1.6	0